{
    "clinical_study": {
        "@rank": "46989", 
        "acronym": "AMA1-DiCo", 
        "arm_group": [
            {
                "arm_group_label": "AMA1-DiCo + Alhydrogel", 
                "arm_group_type": "Experimental", 
                "description": "Group A1 (15):   European volunteer   :  AMA1-DiCo + Alhydrogel\nAMA1-DiCo:  50\u00b5g\nAlhydrogel\u00ae :  0.85 mg Al3+ per dose\nRoute :  Intramuscular Vaccination schedule : Do, W4, W26"
            }, 
            {
                "arm_group_label": "AMA1-DiCo+ GLA-SE", 
                "arm_group_type": "Experimental", 
                "description": "Group A2 (15) :  European volunteer : AMA1-DiCo + GLA-SE\nAMA1-DiCo: 50\u00b5g\nGLA-SE 2.5 \u00b5g GLA per dose\nRoute :  Intramuscular Vaccination schedule : Do, W4, W26"
            }, 
            {
                "arm_group_label": "AMA1-DiCo + GLA-SE", 
                "arm_group_type": "Experimental", 
                "description": "Group B1 (18) :  African  volunteer : AMA1-DiCo + GLA-SE\nAMA1-DiCo: 50\u00b5g\nGLA-SE 2.5 \u00b5g GLA per dose\nRoute :  Intramuscular Vaccination schedule : Do, W4, W26"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Group B2 (18) : African volunteer : Placebo\nPlacebo :  isotonic saline solution\nRoute : Intramuscular Vaccination schedule : Do, W4, W26"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to evaluate the safety of 3 doses given at D0, W4, and W26 of 50 \u00b5g\n      dosage of AMA1-DiCo adjuvanted either with GLA-SE or Alhydrogel\u00ae in healthy European adults\n      not previously exposed to the parasite P.falciparum and in healthy African adults exposed to\n      the parasite. The safety and the tolerability of the vaccine will be assessed on the rate of\n      solicited and unsolicited events/reactions. The safety profile will include local and\n      systemic reactions/events as well as the biological safety, based on a clinically\n      significant change of the baseline value of the main biological criteria."
        }, 
        "brief_title": "Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel \u00ae as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Safety of Candidate Malaria Vaccine", 
        "condition_browse": {
            "mesh_term": "Malaria"
        }, 
        "detailed_description": {
            "textblock": "The project aims  are  :\n\n      -To evaluate the safety of 50 \u00b5g AMA1-DiCo malaria vaccine candidate with GLA-SE and\n      Alhydrogel\u00ae as adjuvant, in healthy European adults not previously exposed to the parasite\n      Plasmodium falciparum and in healthy African adults exposed to the parasite.\n\n      T-o assess the humoral immune response to the vaccine antigens by measuring the level of IgG\n      in all volunteers.\n\n      To assess the cellular immune response by measuring the T cell cytokines IL-5 and IFN\u03b3\n      production following in vitro stimulation with the vaccine antigens in all volunteers.\n\n      Design :\n\n      This trial is a staggered Phase Ia/Ib, Randomised, Double-blind, Multi-center Centre trial.\n\n      Two different adjuvants will be assessed, Alhydrogel\u00ae and GLA-SE. One dosage of 50 \u00b5g/3\n      injections of AMA1-DiCo will be evaluated for each adjuvant.\n\n      Sixty six (66) healthy volunteers will be included into the 2 following cohorts (A and B):\n\n      Cohort A: 30 Non-exposed European Volunteers (France) Cohort B: 36 Malaria Exposed African\n      Volunteers (Burkina Faso)\n\n      The non-exposed European volunteers (cohort A) will be randomised in a 1:1 ratio into two\n      groups of 15 volunteers per group.\n\n      The malaria exposed African volunteers (cohort B) will be randomised in a 1:1 ratio, into\n      two groups of 18 volunteers per group.\n\n      European Volunteers: Cohort A (30):\n\n      Group A1 (15):  50\u00b5g AMA1-DiCo + Alhydrogel\u00ae Group A2 (15): 50 \u00b5g AMA1-DiCo+ GLA-SE\n\n      African Volunteers Cohort B (36) :\n\n      Group B1 (18): 50 \u00b5g AMA1-DiCo + GLA-SE Group B2 (18): Placebo (isotonic saline solution)\n\n      In order to start recruitment in cohort B (Africa), the safety will be evaluated on the data\n      of all European volunteers until Day 7 after 1st immunisation of the last European volunteer\n      Data will be presented to an Independent Data safety Monitoring Board (DSMB) that will be\n      appointed for this trial"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age > 20 and < 45 years healthy female and male\n\n          2. General good health based on history and clinical examination.\n\n          3. Written informed consent obtained before any trial procedure.\n\n          4. Female and male volunteers practicing contraception before and up to four (4) weeks\n             after the third vaccination.\n\n          5. Available to participate in follow-up for the duration of trial.\n\n          6. Reachable by phone during the whole trial period.\n\n          7. Volunteers should be affiliated to a social security regimen\n\n        Exclusion Criteria:\n\n          1. Positive pregnancy test\n\n          2. Active breast feeding\n\n          3. Previous participation  in any malaria vaccine trial\n\n          4. History of blood transfusion within the last 6 months\n\n          5. Symptoms, physical signs or laboratory values suggestive of systemic disorders,\n             including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency,\n             psychiatric and other conditions, which could interfere with the interpretation of\n             the trial results or compromise the health of the volunteers.\n\n          6. Any clinically significant laboratory abnormalities on screened blood samples outside\n             the normal range, as defined at the clinical trial site.\n\n          7. Enrolment in any other clinical trial during the whole trial period\n\n          8. Intake of chronic medication, especially immunosuppressive agents (steroids,\n             immunomodulating or immunosuppressive drugs) during the thirteen weeks preceding the\n             screening visit or during the trial period except topical steroid use including\n             intranasal.\n\n          9. Any confirmed or suspected immunosuppressive or immunodeficiency condition during the\n             whole trial period\n\n         10. Volunteers unable to be closely followed for social, geographic or psychological\n             reasons.\n\n         11. Previous history of drug or alcohol abuse interfering with normal social function\n             during a period of one year prior to enrolment in the trial.\n\n         12. History of anaphylaxis or Known severe hypersensitivity to any of the vaccine\n             components (adjuvant or antigen or excipient)\n\n         13. Vaccination or gamma globulin: 4 weeks prior and after each vaccination if a\n             vaccination is necessary during this period, the volunteer will be withdrawn from the\n             study.\n\n         14. Positive HIV, HBV (Ag HBS) and HCV tests.\n\n         15. History of malaria or travel in malaria endemic areas within the past twenty-six\n             weeks.\n\n         16. Positive serology for malaria antigen PfAMA-1\n\n         17. Intention to travel to malaria endemic countries during the trial period.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014727", 
            "org_study_id": "C12-18  AMA-DiCo", 
            "secondary_id": "2013-001920-20"
        }, 
        "intervention": [
            {
                "arm_group_label": "AMA1-DiCo + Alhydrogel", 
                "intervention_name": "Group A1  :   50\u00b5g AMA1-DiCo + Alhydrogel", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "AMA1-DiCo+ GLA-SE", 
                    "AMA1-DiCo + GLA-SE"
                ], 
                "intervention_name": "Group A2 : 50 \u00b5g AMA1-DiCo+ GLA-SE", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Group B2 : Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aluminum Hydroxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Malaria vaccine", 
            "phase 1,", 
            "AMA1-DiCO"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": [
            {
                "contact": {
                    "email": "s.sirima.cnlp@fasonet.bf;", 
                    "last_name": "Sodiomon Sirima", 
                    "phone": "Tel : + 226 50 32 46 95/6"
                }, 
                "contact_backup": {
                    "email": "agansane.cnrfp@fasonet.bf", 
                    "last_name": "Adama Gansane", 
                    "phone": "(00226)50-32-46-95 / 96"
                }, 
                "facility": {
                    "address": {
                        "city": "Ouagadougou", 
                        "country": "Burkina Faso"
                    }, 
                    "name": "CNRFP"
                }, 
                "investigator": {
                    "last_name": "Sodiomon Sirima", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "odile.launay@cch.aphp.fr", 
                    "last_name": "Odile Launay, Professor", 
                    "phone": "331 58 41 28 60"
                }, 
                "contact_backup": {
                    "email": "leila.kara@cch.aphp.fr", 
                    "last_name": "Leila Kara", 
                    "phone": "331 58 41 23 11"
                }, 
                "facility": {
                    "address": {
                        "city": "H\u00f4pital Cochin B\u00e2timent Lavoisier 27 rue du faubourg St Jacqu", 
                        "country": "France", 
                        "state": "Paris", 
                        "zip": "75014"
                    }, 
                    "name": "CIC BT 505 de vaccinologie Cochin Pasteur"
                }, 
                "investigator": {
                    "last_name": "Odile Launay", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Burkina Faso", 
                "France"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel \u00ae as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial", 
        "other_outcome": {
            "description": "The quality of the humoral immune response will be assessed by measuring:\nIgG1 and IgG3 subclasses by ELISA on samples obtained at Day 0 and Week 30. IgG responses to four natural allelic variants by ELISA on samples obtained at Days 0 and Week 30.\nAn IFA will be employed to verify that the antibodies elicited by the vaccine recognize the native protein on merozoites on samples obtained Day 0 and Week 30.\nCompetition ELISA with AMA1 antigen added as competitor at Week 30. The ability to inhibit parasite growth in vitro by a Growth Inhibition Assay (GIA) against at least 3 parasite strains on samples obtained at Day 0, Week 30 and 52.\nIgG avidity by ELISA on a panel of AMA1 alleles at Week 30.\nThe quality of the cellular immune response will be assessed by measuring the production of a panel of T cell cytokines in the ELISpot supernatants by multiplex cytokine assay on samples obtained at Day 0, Week 26, 30 and 52.", 
            "measure": "The quality of the  cellular and humoral immune responses", 
            "safety_issue": "No", 
            "time_frame": "Up to  6 months after the last vaccination"
        }, 
        "overall_contact": {
            "email": "odile.launay@cch.aphp.fr", 
            "last_name": "Odile Launay", 
            "phone": "0033 158412860"
        }, 
        "overall_official": [
            {
                "affiliation": "CIC BT505 Cochin Pasteur  Groupe Hospitalier Cochin Broca Hotel Dieu. B\u00e2timent Lavoisier  27, rue du Faubourg Saint-Jacques 75679 PARIS Cedex 14, France odile.launay@cch.aphp.fr", 
                "last_name": "Odile Launay, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre National de Recherche et de Formation sur le Paludisme (CNRFP 01 BP 2208 Ouagadougou 01 1487, Avenue KumdaYonr\u00e9, Burkina Faso s.sirima.cnlp@fasonet.bf", 
                "last_name": "Sodiomon Sirima, Doctor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Burkina Faso : Direction G\u00e9n\u00e9rale de la Pharmacie, du M\u00e9dicament et des Laboratoires"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The safety profile will be assessed in all volunteers on the following criteria:\nImmediate reactogenicity (reactions within 60 minutes after each vaccination).\nLocal and systemic reactogenicity measured from Day 0 to Week 2 after each vaccination.\nAny unsolicited adverse event between the first vaccination and four weeks after the third vaccination.\nAny SAE occurring from the inclusion throughout the trial.", 
            "measure": "Number of Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to  four weeks after the third vaccination."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014727"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The humoral response to the vaccine antigens (DiCo1, DiCo2 and DiCo3) will be assessed by measuring the level of IgG by ELISA on samples obtained at screening visit Day 0, Week 4, 5, 8, 26, 27, 30 and 52.\nThe cellular immune response will be assessed by measuring the T cell cytokine IL-5, and IFNg production by ELISpot following in vitro stimulation with the vaccine antigens on samples obtained at Day 0, Week 26, 30 and 52.", 
            "measure": "The humoral  and  cellular responses", 
            "safety_issue": "No", 
            "time_frame": "6 months after the last vaccination"
        }, 
        "source": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "EVI", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "BPRC", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "CIC COCHIN", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "CNRFP", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}